Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06242795 · ClinicalTrials.gov registry record · Phase 4
Hypertonic Saline in NCFB
A Phase 4 study of Bronchiectasis and Non-cystic Fibrosis Bronchiectasis, sponsored by University of North Carolina, Chapel Hill.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06242795: Recruiting Phase 4 study of Bronchiectasis and Non-cystic Fibrosis Bronchiectasis, sponsored by University of North Carolina, Chapel Hill.
NCT06242795 is a Phase 4 study of Bronchiectasis and Non-cystic Fibrosis Bronchiectasis that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 20 participants, below the 386-participant average among 13 other Bronchiectasis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06242795, a Phase 4 study of Bronchiectasis and Non-cystic Fibrosis Bronchiectasis, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this single arm clinical trial is to evaluate the effects of 7% hypertonic saline (HS) delivered by nebulizer on clearance of mucus from the lungs in people with bronchiectasis (dilated airways) not due to cystic fibrosis. Mucociliary clearance (MCC) to measure the rate at which a person's lungs can clear inhaled particles will be assessed at baseline, and after acute (single dose) HS treatment, as well as after two weeks of treatment with HS. The study has two main questions: 1. Evaluate the repeatability MCC measures in people with non-CF bronchiectasis 2. Compare MCC at baseline (before treatment with HS), after a single dose of HS (acute effect of HS), and after two weeks of treatment with HS twice a day (sustained effect of HS). Participants will participate in up to 5 study visits if completing both Aim 1 and Aim 2: 1 screening/enrollment visit, 2 baseline visits (1 baseline visit if only participating in Aim 2), 1 visit during which first dose of HS would be administered and assessed, and 1 visit after 2 weeks of treatment with HS.
Primary Outcome
The primary outcome for Aim 1 will be the correlation between the average rate of MCC measured in the whole right lung compartment over 60 minutes (MCC60), calculated using point estimates collected every 10 minutes, assessed from two separate visits (Visit 2 and Visit 3)
Conditions Studied
Interventions
- DRUG 7% Hypertonic Saline via nebulization
Study Locations (1)
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-10-23 |
| Est. Completion | 2026-06 |
| Phase | Phase 4 |
What NCT06242795 shows while recruiting
NCT06242795 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 386-participant average among 13 other Bronchiectasis trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Bronchiectasis appearing as the primary indexed condition, and to 1 intervention - of which 7% Hypertonic Saline via nebulization is the first listed.
NCT06242795 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06242795 about?
NCT06242795 is a clinical study titled "Hypertonic Saline in NCFB". The purpose of this single arm clinical trial is to evaluate the effects of 7% hypertonic saline (HS) delivered by nebulizer on clearance of mucus from the lungs in people with bronchiectasis (dilated airways) not due to cystic fibrosis. Mucociliary clearance (MCC) to measure the rate at which a per...
What is the current status of trial NCT06242795?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2024-10-23. Estimated completion is 2026-06.
What conditions does trial NCT06242795 study?
This clinical trial studies the following conditions: Bronchiectasis, Non-cystic Fibrosis Bronchiectasis.
What interventions are being tested in trial NCT06242795?
The interventions under investigation include: 7% Hypertonic Saline via nebulization (DRUG).
Who is sponsoring clinical trial NCT06242795?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06242795 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bronchiectasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06242795's enrollment target sits among peer trials
20 13th of 13 higher than 1 of 13 other Bronchiectasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bronchiectasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Itraconazole Therapy In Bronchiectasis With Airway Mold
RECRUITING · Phase 4
-
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
RECRUITING · Phase 3
-
Evaluation Of The Lung Microbiome In NTM Bronchiectasis
RECRUITING
-
Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease
RECRUITING · NA
-
OLE Therapy With BE Patients in Home Care Study
RECRUITING · NA
-
Natural History of Bronchiectasis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI